Enliven Therapeutics (NASDAQ:ELVN) Earns Buy Rating from HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $37.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 46.25% from the company’s previous close.

Several other research analysts have also weighed in on the company. Robert W. Baird assumed coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price objective for the company. Baird R W raised Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th.

Enliven Therapeutics Trading Down 2.7 %

Shares of ELVN stock opened at $25.30 on Tuesday. Enliven Therapeutics has a twelve month low of $9.80 and a twelve month high of $27.67. The company’s 50-day moving average price is $23.19 and its 200-day moving average price is $21.84. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -13.11 and a beta of 1.09.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.17. As a group, equities research analysts predict that Enliven Therapeutics will post -1.98 EPS for the current year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $24.92, for a total value of $299,040.00. Following the completion of the transaction, the chief executive officer now owns 1,063,525 shares in the company, valued at $26,503,043. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Benjamin Hohl sold 4,250 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $24.27, for a total transaction of $103,147.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 125,805 shares of company stock worth $3,126,077. Insiders own 29.20% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently modified their holdings of the business. Quest Partners LLC raised its stake in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after acquiring an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Enliven Therapeutics by 67.0% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares during the period. American Century Companies Inc. raised its position in Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after purchasing an additional 8,540 shares in the last quarter. EntryPoint Capital LLC purchased a new position in shares of Enliven Therapeutics in the 1st quarter valued at about $167,000. Finally, Rhumbline Advisers increased its stake in shares of Enliven Therapeutics by 29.9% during the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after buying an additional 11,420 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.